We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATHX
201
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$253 0.01%
64
+23
+56% +$795
AMT icon
202
PUT
American Tower
AMT
$80.7B
$247 0.01%
25
– –
CYH icon
203
CALL
Community Health Systems
CYH
$388M
$226 0.01%
+51
New +$2.18K
SMLR
204
DELISTED
Semler Scientific
SMLR
$226 0.01%
115,423
-166,528
-59% -$400K
ALT icon
205
CALL
Altimmune
ALT
$580M
$221 0.01%
4
– –
RXII
206
DELISTED
GALENA BIOPHARMA INC COM
RXII
$213 0.01%
140,944
-141,760
-50% -$214
PLUR icon
207
PUT
Pluri
PLUR
$17.3M
$193 0.01%
10
-31
-76% -$6.74K
LXRX icon
208
Lexicon Pharmaceuticals
LXRX
$1.03B
$184 0.01%
+28,957
New +$233K
KERX
209
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$181 0.01%
128
+28
+28% +$434
ARIA
210
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$178 0.01%
259
-2,013
-89% -$12.6K
HSTO
211
CALL
DELISTED
Histogen Inc. Common Stock
HSTO
$118 ﹤0.01%
+1
New +$1.45K
DARA
212
DELISTED
DARA BIOSCIENCES INC COM STK (DE)
DARA
$110 ﹤0.01%
+124,890
New +$105K
STAB
213
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$108 ﹤0.01%
18,858
-25,195
-57% -$197K
HCA icon
214
CALL
HCA Healthcare
HCA
$91.9B
$107 ﹤0.01%
+192
New +$13.5K
TXMD icon
215
CALL
TherapeuticsMD
TXMD
$23.7M
$95 ﹤0.01%
+4
New +$825
CRDF icon
216
Cardiff Oncology
CRDF
$61M
$86 ﹤0.01%
278
– –
ATHX
217
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$80 ﹤0.01%
20
-6
-23% -$207
EXEL icon
218
Exelixis
EXEL
$14B
$66 ﹤0.01%
45,622
-235,700
-84% -$367K
CTIC
219
PUT
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$60 ﹤0.01%
26
– –
GALT icon
220
Galectin Therapeutics
GALT
$232M
$55 ﹤0.01%
+15,842
New +$70K
CERE
221
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$53 ﹤0.01%
27,825
-34,675
-55% -$82K
IPCI
222
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$47 ﹤0.01%
+2,063
New +$55.8K
ARNA
223
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$45 ﹤0.01%
13
-218
-94% -$8.85K
FOCL
224
PUT
EDAP TMS S.A.
FOCL
$231M
$39 ﹤0.01%
168
+29
+21% +$52
CYTR
225
PUT
DELISTED
CytRx Corp
CYTR
$27 ﹤0.01%
+17
New +$265
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.